By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Melanomas is the subject of a report. According to news reporting originating from Wuhan, People's Republic of China, by NewsRx correspondents, research stated, "The authors aimed to investigate whether nanotechnology-based delivery of antigenic peptides is feasible for efficiently inducing anti-tumor cytotoxic T lymphocyte responses through vaccination. Three different murine melanoma antigens were entrapped in lipid-coated poly(D, L-lactide-co-glycolide) nanoparticles (NPs) by the double emulsion method."
Our news editors obtained a quote from the research from the Huazhong University of Science and Technology, "The loading efficiency of hydrophilic peptides was greatly improved when lipids were introduced to formulate lipid-coated NPs. The lipid-coated NPs carrying a single peptide and/or combinations of multiple lipid-coated NPs carrying antigenic peptides were characterized in vitro and in vivo in a C57/BL6 (B6) mouse model. Both the single melanoma antigen peptide-loaded NPs and combinational delivery of lipid-coated NPs carrying different peptides could induce antigen-specific T-cell responses. However, single peptide-loaded NPs failed to significantly delay the growth of subcutaneously inoculated B16 melanoma cells in a prophylactic setting."
According to the news editors, the research concluded: "By contrast, the combinational delivery of lipid-coated NPs carrying different peptides significantly suppressed growth of inoculated B16 melanoma cells."
For more information on this research see: Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy. Nanomedicine, 2014;9(5):635-647. Nanomedicine can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
The news editors report that additional information may be obtained by contacting S.W. Tan, Huazhong University of Science & Technology, Union Hosp, Tongji Med College, Center Canc, Wuhan 430030, People's Republic of China. Additional authors for this research include T. Sasada, A. Bershteyn, K.Y. Yang, T. Ioji and Z.P. Zhang (see also Melanomas).
Keywords for this news article include: Asia, Wuhan, Peptides, Proteins, Melanomas, Amino Acids, Nanoparticle, Immunotherapy, Nanotechnology, Immunomodulation, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC